Butaclamol

This classification denotes a dopamine antagonist with the molecular formula C25H31NO, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier A7A2802VNL, chemically known as 1h-benzo(6,7)-cyclohepta(1,2,3-de)pyrido(2,1-a)isoquinolin-3-ol, 3-(1,1-dimethylethyl)-2,3,4,4a,8,9,13b,14-octahydro-, (3alpha,4aalpha,13bbeta)-(+-)- but generally known as butaclamol, which bears US NIH Compound Identifier 37459. Butaclamol most often comes in base and hydrochloride forms. European Medicines Agency schedules Butaclamol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05995MIG. The term BUTACLAMOL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 28, No. 10 1974, List 14). BUTACLAMOL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule butaclamol under HS 29339990 and SITC 51577. As of Q4 2014, BUTACLAMOL remains the US FDA Preferred Term for this commodity. Butaclamol bears US NLM identifiers UMLS ID C0006467 and NCI Concept Code C81088. SMILES: OC1(CC2N(CC1)CC1C3C2CCCC3CCC2C1CCCC2)C(C)(C)C.